suPAR abstract wins 1. prize at DEMC7 Emergency Conference

Thu Dec 01 2016

Line J. H. Rasmussen at Copenhagen's DEMC7

Line Jee Hartmann Rasmussen unveiled pioneering results at Copenhagen’s DEMC7, northern Europe’s top Emergency Medicine Conference, on November 25. Her abstract, “suPAR as a standard prognostic test in the Acute Medical Unit at Hvidovre Hospital,” clinched both an oral presentation and the coveted 1st prize.

Evaluating suPAR as a Prognostic Test

The study analyzed suPAR’s prognostic value, a biomarker linked to inflammation and immunity, in 17,312 acute patients. Researchers assessed suPAR’s ability to predict readmission rates and survival in-depth.

Impact of suPAR Levels on Patient Outcomes

The findings of the study provided valuable insights into the impact of suPAR levels on various aspects of patient outcomes. High suPAR levels were found to be strongly correlated with increased comorbidities, both in terms of their number and severity. This observation underscores the role of suPAR as a potential indicator of overall health status and disease burden.

Furthermore, the study revealed that patients with high suPAR levels experienced longer hospital admissions. This extended length of stay may reflect the complexity of their conditions or the need for more intensive monitoring and treatment. These findings emphasize the utility of suPAR as a tool for risk stratification and resource allocation in acute medical settings.

The study’s most remarkable finding highlighted the link between elevated suPAR levels and adverse clinical outcomes. Patients with higher suPAR levels experienced substantially increased readmission rates, underscoring suPAR’s ability to pinpoint individuals at risk of recurring hospitalization. Moreover, patients exhibiting high suPAR levels had notably raised mortality rates, further underscoring suPAR’s robust predictive capability for survival outcomes.

In summary, the study at Hvidovre Hospital presented compelling evidence supporting the use of suPAR as a standard prognostic test. These findings indicate that high suPAR was associated with :
– Increased number and severity of comorbidities
– Longer admission time
– High readmission rate – High mortality rate

suPAR remained an independent predictor after adjustment for age, sex, Charlson score, and CRP.

Please find the poster on Lines abstract here

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

suPARnostic POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates